Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer

David J. Pinato; Petros Fessas; Alessio Cortellini; Lorenza Rimassa

doi:10.1158/1078-0432.CCR-20-4069

Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer

David J. Pinato, Petros Fessas, Alessio Cortellini, Lorenza Rimassa

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.

Lingua originale	Inglese
pagine (da-a)	908-910
Numero di pagine	3
Rivista	Clinical Cancer Research
Volume	27
Numero di pubblicazione	4
DOI	https://doi.org/10.1158/1078-0432.CCR-20-4069
Stato di pubblicazione	Pubblicato - 15 feb 2021
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1158/1078-0432.CCR-20-4069

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{bf2db881fe9d4be79a2f420e90d70409,

title = "Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer",

abstract = "Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.",

author = "Pinato, {David J.} and Petros Fessas and Alessio Cortellini and Lorenza Rimassa",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2021",

month = feb,

day = "15",

doi = "10.1158/1078-0432.CCR-20-4069",

language = "English",

volume = "27",

pages = "908--910",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

TY - JOUR

T1 - Combined PD-1/VEGFR Blockade

T2 - A New Era of Treatment for Hepatocellular Cancer

AU - Pinato, David J.

AU - Fessas, Petros

AU - Cortellini, Alessio

AU - Rimassa, Lorenza

PY - 2021/2/15

Y1 - 2021/2/15

N2 - Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.

AB - Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.

UR - http://www.scopus.com/inward/record.url?scp=85101741319&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-4069

DO - 10.1158/1078-0432.CCR-20-4069

M3 - Review article

SN - 1078-0432

VL - 27

SP - 908

EP - 910

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo